Dilated Cardiomyopathy Drug Development Outlook 2025: 8+ Active Players and 8+ Pipeline Therapies Under Review, analyses DelveInsight

DelveInsight's "Dilated Cardiomyopathy Pipeline Insight" report offers in-depth analysis of more than 8 companies and 8 pipeline candidates shaping the Dilated Cardiomyopathy (DCM) development landscape.

The report presents detailed profiles of pipeline drugs across both clinical and preclinical stages. It also evaluates the DCM therapeutic landscape based on product classification, development phase, route of administration, and molecule category. In addition, the report identifies discontinued and inactive assets within this therapeutic area.

Explore the newest treatment candidates and innovations in the Dilated Cardiomyopathy pipeline by accessing DelveInsight's comprehensive analysis today: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Dilated Cardiomyopathy Pipeline Report
• February 2026 - Affinia Therapeutics has received approval from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application to initiate the UPBEAT Phase I/II trial of AFTX-201.
• December 2025 - Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZOTM (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
• December 03, 2025 - Kardigan, Inc. initiated a clinical study to assess the efficacy and safety of danicamtiv versus placebo in patients diagnosed with genetic and familial Dilated Cardiomyopathy. DCM is characterized by weakened and enlarged heart muscle, leading to reduced pumping efficiency. Genetic DCM results from identifiable gene mutations, while familial DCM occurs within families even without a confirmed genetic variant.
• December 03, 2025 - Alexion Pharmaceuticals Inc. announced an open-label Phase I/II dose-escalation and dose-expansion trial evaluating the safety, tolerability, and therapeutic potential of a single intravenous dose of ALXN2350 in adult patients with BAG3-associated Dilated Cardiomyopathy.
• DelveInsight's analysis highlights a strong and evolving pipeline, with over 8 active companies collectively developing more than 8 investigational therapies for Dilated Cardiomyopathy.
• Key players operating in the Dilated Cardiomyopathy space include Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics, among others.
• Notable therapeutic candidates under development for Dilated Cardiomyopathy include Carvedilol, Metoprolol Succinate, ARRY-371797, Danicamtiv, Ifetroban, ALXN2350, and several others.

Stay informed with the latest updates on Dilated Cardiomyopathy drug development, clinical studies, and key industry players with DelveInsight: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Dilated Cardiomyopathy Pipeline Report delivers a thorough disease background, an overview of the current pipeline scenario, and an in-depth therapeutic assessment of key drug candidates. The report also outlines critical unmet medical needs associated with Dilated Cardiomyopathy.

Dilated Cardiomyopathy Overview
Dilated Cardiomyopathy (DCM) is a cardiac disorder marked by enlargement and weakening of the left ventricle, the heart's primary pumping chamber, which compromises its ability to circulate blood effectively. As the ventricular walls stretch and thin, patients may experience symptoms such as fatigue, breathlessness, peripheral edema, and cardiac arrhythmias. DCM may arise due to genetic factors, viral infections, excessive alcohol intake, autoimmune diseases, certain medications, or idiopathic causes. Without treatment, the condition can advance to heart failure; however, early diagnosis and appropriate therapy can help many individuals manage symptoms and maintain quality of life.

Dilated Cardiomyopathy Emerging Drug Profiles
• BC 007 - Berlin Cures
BC 007 (Rovunaptabin) is an innovative investigational therapy being developed for Dilated Cardiomyopathy. Berlin Cures has engineered a DNA-based aptamer designed to selectively bind and neutralize pathogenic autoantibodies targeting G protein-coupled receptors. In an open-label Phase IIa clinical study involving heart failure patients, a single administration of BC 007 resulted in sustained neutralization of these functional autoantibodies. In contrast, patients in the untreated control arm remained autoantibody-positive throughout the study period. Encouraged by these findings and the significant unmet need, Berlin Cures plans to progress BC 007 into a controlled Phase IIb trial in heart failure patients. The therapy is currently in Phase II development for Dilated Cardiomyopathy.
• AZD0233 - AstraZeneca
AZD0233 is a novel investigational compound developed by AstraZeneca and administered orally. The drug is currently undergoing Phase I clinical evaluation for the treatment of Dilated Cardiomyopathy.

Discover next-generation therapies and ongoing clinical trials in the Dilated Cardiomyopathy pipeline by accessing DelveInsight's detailed report: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Dilated Cardiomyopathy Pipeline Report Offers Insights Into
• Comprehensive profiling of companies actively developing Dilated Cardiomyopathy therapies, including the number of assets per company
• Classification of pipeline candidates into early-, mid-, and late-stage development categories
• Analysis of both active and inactive (discontinued or dormant) drug development programs
• Segmentation of pipeline drugs by development stage, route of administration, molecular class, target receptor, mechanism of action, and therapy type (monotherapy or combination)
• Detailed review of strategic collaborations, licensing agreements, and funding activities influencing future market growth

Dilated Cardiomyopathy Companies
Major companies engaged in the Dilated Cardiomyopathy pipeline include Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics, and others.

The report also evaluates pipeline therapies based on Route of Administration (ROA), including:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Dilated Cardiomyopathy therapies are further categorized by Molecule Type, such as:
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

Gain forward-looking insights into Dilated Cardiomyopathy drug development and emerging opportunities with DelveInsight's expert assessment: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Dilated Cardiomyopathy Pipeline Report
• Geographical Coverage: Global
• Key Companies: Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics, and others
• Key Therapies: Carvedilol, Metoprolol Succinate, ARRY-371797, Danicamtiv, Ifetroban, ALXN2350, among others
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, Mono/Combination
• Therapeutic Assessment by Development Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Access the most recent updates on Dilated Cardiomyopathy therapies and clinical advancements by downloading DelveInsight's in-depth pipeline report: https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Dilated Cardiomyopathy: Disease Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. DelveInsight's Analytical Perspective on Dilated Cardiomyopathy
7. Late-Stage Pipeline Products (Phase III)
8. Emprumapimod - Pfizer
9. Mid-Stage Pipeline Products (Phase I/II)
10. Mesenchymal Stem Cell Therapy - Longeveron
11. Early-Stage Pipeline Products (Phase I)
12. Preclinical Pipeline Assets
13. CDR 426D - Cardior Pharmaceuticals
14. Inactive Pipeline Assets
15. Key Companies in Dilated Cardiomyopathy
16. Key Pipeline Products
17. Unmet Medical Needs in Dilated Cardiomyopathy
18. Market Drivers and Barriers
19. Future Outlook and Conclusions
20. Analyst Perspectives
21. Key Companies
22. Appendix

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a globally recognized healthcare market research and consulting firm delivering high-quality, actionable intelligence to support strategic decision-making. Backed by experienced life sciences and healthcare experts, DelveInsight provides customized research solutions and real-time insights to clients worldwide. Partner with DelveInsight to gain accurate, timely intelligence and stay ahead in a rapidly evolving healthcare landscape.

This release was published on openPR.